Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Depreciation & Amortization (CF): 2019-2025

Historic Depreciation & Amortization (CF) for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to $2.1 million.

  • Revolution Medicines' Depreciation & Amortization (CF) rose 25.64% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year increase of 18.35%. This contributed to the annual value of $6.6 million for FY2024, which is 30.09% up from last year.
  • Per Revolution Medicines' latest filing, its Depreciation & Amortization (CF) stood at $2.1 million for Q3 2025, which was up 17.35% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Depreciation & Amortization (CF) registered a high of $2.1 million during Q3 2025, and its lowest value of $671,000 during Q1 2021.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $1.6 million (2024), whereas its average is $1.6 million.
  • Data for Revolution Medicines' Depreciation & Amortization (CF) shows a peak YoY surged of 37.94% (in 2022) over the last 5 years.
  • Revolution Medicines' Depreciation & Amortization (CF) (Quarterly) stood at $833,000 in 2021, then surged by 37.94% to $1.1 million in 2022, then rose by 13.14% to $1.3 million in 2023, then soared by 33.46% to $1.7 million in 2024, then rose by 25.64% to $2.1 million in 2025.
  • Its Depreciation & Amortization (CF) was $2.1 million in Q3 2025, compared to $1.8 million in Q2 2025 and $1.7 million in Q1 2025.